TNFRSF8 and synovial sarcoma: To address this clinically relevant question, we conducted a retrospective study within the German Cutaneous Lymphoma Network to characterize treatment patterns and the duration of benefit from BV in patients with advanced-stage MF/SS and low CD30 expression (5–9% and <5%).